| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Stefan Michiels | Q41044549 |
| P2093 | author name string | R W Carlson | |
| M O'Connell | |||
| J P Pignon | |||
| M Buyse | |||
| P Piedbois | |||
| Meta-Analysis Group in Cancer | |||
| P Thirion | |||
| P Sargent | |||
| A C Braud | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| fluorouracil | Q238512 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 3766-3775 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis | |
| P478 | volume | 22 |
| Q33425826 | A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer |
| Q59813330 | A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients |
| Q36614969 | A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer |
| Q34798367 | A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study |
| Q38551668 | A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer |
| Q33420046 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer |
| Q36667516 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer |
| Q36627201 | A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer |
| Q53648255 | A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. |
| Q45945682 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. |
| Q34344012 | A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer |
| Q36661290 | A review of the role of capecitabine in the treatment of colorectal cancer. |
| Q35756882 | A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer |
| Q36847302 | A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. |
| Q36659821 | A systematic review on drug interactions in oncology |
| Q24632539 | ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients |
| Q64084991 | Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review |
| Q38707832 | Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies |
| Q34725978 | Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. |
| Q38124755 | Advances and directions in chemotherapy using implantable port systems for colorectal cancer: a historical review |
| Q37060175 | Advances in chemotherapy against advanced or metastatic colorectal cancer |
| Q37867126 | Advances in regional chemotherapy of the liver |
| Q84972669 | Advances in the treatment of metastatic colorectal cancer |
| Q33530405 | Antimetabolites and cancer: emerging data with a focus on antifolates |
| Q38617495 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer |
| Q37634940 | Bystander or no bystander for gene directed enzyme prodrug therapy |
| Q64284156 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III t |
| Q37122339 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients |
| Q36548730 | Capecitabine in carcinoma of the pancreas. |
| Q37154737 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence |
| Q36757711 | Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma |
| Q33960370 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial |
| Q37118923 | Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer |
| Q37802537 | Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection |
| Q53855896 | Chemotherapy of Metastatic Colorectal Cancer. |
| Q37774285 | Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases |
| Q38843951 | Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan |
| Q46567893 | Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial |
| Q37030059 | Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment |
| Q34663557 | Colorectal hepatic metastasis: Evolving therapies |
| Q37449224 | Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer |
| Q43444041 | Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients |
| Q36598736 | Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer |
| Q33434559 | Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer |
| Q36870003 | Cost considerations in the treatment of colorectal cancer |
| Q38810330 | Cost-effectiveness of cetuximab for colorectal cancer |
| Q43253004 | Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing |
| Q36960766 | Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach |
| Q33418614 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). |
| Q39349619 | Decision Making in Interventional Oncology: Intra-arterial Therapies for Metastatic Colorectal Cancer-Y90 and Chemoembolization |
| Q39041183 | Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles |
| Q31092632 | Determination of reduced folates in tumor and adjacent mucosa of colorectal cancer patients using LC-MS/MS. |
| Q34694410 | ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis |
| Q38155482 | Emerging treatments in recurrent and metastatic colorectal cancer. |
| Q35672166 | Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes |
| Q37360585 | Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy |
| Q36307888 | Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy |
| Q36611396 | Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. |
| Q36760297 | First-line treatment strategies for elderly patients with metastatic colorectal cancer |
| Q47430316 | Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials |
| Q34538305 | Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages |
| Q37326863 | Future of targeted agents in metastatic colorectal cancer |
| Q37697618 | Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis |
| Q36252178 | Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. |
| Q53206717 | High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer. |
| Q80408154 | Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007 |
| Q43648730 | Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection |
| Q58786116 | Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience |
| Q37602294 | Impact of molecular markers on treatment selection in advanced colorectal cancer |
| Q47101871 | Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology |
| Q24200737 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer |
| Q24186145 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer |
| Q41830454 | Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases |
| Q45105112 | Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer |
| Q33638165 | Longitudinal assessment of colonic tumor fate in mice by computed tomography and optical colonoscopy |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q36533867 | Management of advanced colorectal cancer: state of the art. |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q36920617 | Metastatic colorectal cancer: current systemic treatment options. |
| Q36216117 | Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer |
| Q36879172 | New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. |
| Q36677474 | Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. |
| Q33522017 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials |
| Q46261446 | PPARγ sumoylation-mediated lipid accumulation in lung cancer |
| Q36169867 | Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience |
| Q36989058 | Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older |
| Q33563293 | Patient considerations in metastatic colorectal cancer - role of panitumumab |
| Q34731381 | Personalized colon cancer care in 2010. |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q36621562 | Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer |
| Q53641063 | Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. |
| Q33403227 | Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer |
| Q37481906 | Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer |
| Q33751177 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer |
| Q42288648 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. |
| Q33428967 | Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer |
| Q45288765 | Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer |
| Q37655339 | Prediagnostic plasma folate and the risk of death in patients with colorectal cancer |
| Q37353936 | Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? |
| Q35556037 | Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time |
| Q87163239 | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i |
| Q34998310 | Prolonged survival in metastatic colorectal cancer following chemotherapy |
| Q38621699 | Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. |
| Q36792353 | Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis |
| Q64911501 | Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer. |
| Q33455278 | Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q34099115 | Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma |
| Q97589307 | S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial |
| Q38660442 | S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial |
| Q87273865 | S-1 with leucovorin and oxaliplatin for advanced gastric cancer |
| Q53449253 | Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy |
| Q37602729 | Sequencing of treatment in metastatic colorectal cancer: where to fit the target |
| Q38216008 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? |
| Q36391403 | Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? |
| Q36727471 | Surrogate endpoint analysis: an exercise in extrapolation |
| Q46987043 | Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis |
| Q37345922 | Systemic and targeted therapy for advanced colon cancer |
| Q81253030 | Systemic treatment of colorectal cancer |
| Q36217126 | Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report |
| Q37924094 | Targeting cancer metabolism: a therapeutic window opens |
| Q39233316 | The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. |
| Q42700710 | The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials |
| Q41713124 | The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis |
| Q34773758 | The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials |
| Q37831218 | The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? |
| Q54394304 | Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy. |
| Q37427386 | Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer |
| Q38531685 | Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review |
| Q33320407 | Two simple approaches for validating a binary surrogate endpoint using data from multiple trials |
| Q36452865 | Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study |
| Q38997864 | Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. |
| Q79769145 | [A review of chemotherapy for metastatic colon cancer] |
| Q45990468 | [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. |
| Q47262466 | iTRAQ Quantitative Proteomic Profiling and MALDI-MSI of Colon Cancer Spheroids Treated with Combination Chemotherapies in a 3D Printed Fluidic Device. |
Search more.